Consult the medical resource doctors trust

UpToDate is one of the most respected medical information resources in the world, used by over 360,000 doctors and thousands of patients to find answers to medical questions.

  • Content written by a faculty of over 4,000 physicians from leading medical institutions
  • Unbiased: free of advertising or pharmaceutical funding
  • Evidence-based treatment recommendations
  • Continuously updated to incorporate new medical findings

Pulmonary complications of inflammatory bowel disease

INTRODUCTION

A variety of conditions arise outside of the gastrointestinal tract that are associated with inflammatory bowel disease (IBD); these are termed extraintestinal manifestations of IBD (table 1). Involvement of the respiratory tract, although relatively rare, is increasingly recognized in patients with inflammatory bowel disease (IBD) since the original report in 1976 of six patients with unexplained chronic purulent sputum production [1]. These abnormalities are generally related to the underlying bowel disease, although interstitial lung disease can also be induced by administration of certain drugs, including sulfasalazine, 5-aminosalicylic acid, methotrexate, azathioprine, and infliximab [2-6].

The pulmonary complications of IBD and those related to the various therapies for IBD are discussed here. An approach to interstitial pneumonitis and a discussion of the clinical manifestations of Crohn's disease and ulcerative colitis are provided separately. (See "Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults" and "Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults".)

PRIMARY RESPIRATORY INVOLVEMENT

Pulmonary complications of IBD include airway inflammation involving small and large airways, pulmonary parenchymal disease, and serositis [7,8]. In one study, reporting 33 new cases and reviewing an additional 98 cases from the literature, approximately 41 percent of the patients presented with some form of airway inflammation, 27 percent with lung parenchymal involvement, and 17 percent had involvement of the pleura; an additional 15 percent had myo/pericarditis (table 2) [9].

The pathogenesis of the pulmonary parenchymal disease and the serositis is unknown. However, the more common airway inflammatory changes have been thought to represent the same type of inflammatory changes that occur in the bowel [10]. (See "Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease" and "Immunologic basis for extraintestinal manifestations in inflammatory bowel disease".)

Airway inflammation — Inflammation of the trachea, bronchi, and bronchioles can occur in inflammatory bowel disease, with bronchial involvement being most common [9-12].

To continue reading this article you need to subscribe.

Read the rest of this article and others like it

The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use (click here) ©2010 UpToDate, Inc.
References Top
  1. Kraft, SC, Earle, RH, Roesler, M, Esterly, JR. Unexplained bronchopulmonary disease with inflammatory bowel disease. Arch Intern Med 1976; 136:454.
  2. Casey, MB, Tazelaar, HD, Myers, JL, et al. Noninfectious lung pathology in patients with Crohn's disease. Am J Surg Pathol 2003; 27:213.
  3. Parry, SD, Barbatzas, C, Peel, ET, Barton, JR. Sulphasalazine and lung toxicity. Eur Respir J 2002; 19:756.
  4. Storch, I, Sachar, D, Katz, S. Pulmonary manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2003; 9:104.
  5. Kuzela, L, Vavrecka, A, Prikazska, M, et al. Pulmonary complications in patients with inflammatory bowel disease. Hepatogastroenterology 1999; 46:1714.
  6. Black, H, Mendoza, M, Murin, S. Thoracic manifestations of inflammatory bowel disease. Chest 2007; 131:524.
  7. Mahadeva, R, Walsh, G, Flower, CD, Shneerson, JM. Clinical and radiological characteristics of lung disease in inflammatory bowel disease. Eur Respir J 2000; 15:41.
  8. Sostegni, R, Daperno, M, Pera, A. Pulmonary manifestations of inflammatory bowel disease. Dig Liver Dis 2007; 39:239.
  9. Camus, P, Piard, F, Ashcroft, T, et al. The lung in inflammatory bowel disease. Medicine 1993; 72:151.
  10. Higenbottam, T, Cochrane, GM, Clark, TJH, et al. Bronchial disease in ulcerative colitis. Thorax 1980; 35:581.
  11. Kuzniar, T, Sleiman, C, Brugiere, O, et al. Severe tracheobronchial stenosis in a patient with Crohn's disease. Eur Respir J 2000; 15:209.
  12. Mansi, A, Cucchiara, S, Greco, L, et al. Bronchial hyperresponsiveness in children and adolescents with Crohn's disease. Am J Respir Crit Care Med 2000; 161:1051.
  13. Garg, K, Lynch, DA, Newell, JD. Inflammatory airways disease in ulcerative colitis: CT and high-resolution CT features. J Thorac Imaging 1993; 8:159.
  14. Spira, A, Grossman, R, Balter, M. Large airway disease associated with inflammatory bowel disease. Chest 1998; 113:1723.
  15. Vandenplas, O, Casel, S, Delos, M, et al. Granulomatous bronchiolitis associated with Crohn's disease. Am J Respir Crit Care Med 1998; 158:1676.
  16. Tzanakis, N, Bouros, D, Samiou, M, et al. Lung function in patients with inflammatory bowel disease. Respir Med 1998; 92:516.
  17. Marvisi, M, Borrello, PD, Brianti, M, et al. Changes in the carbon monoxide diffusing capacity of the lung in ulcerative colitis. Eur Respir J 2000; 16:965.
  18. Theodoropoulos, G, Archimandritis, A, Davaris, P, et al. Ulcerative colitis and sarcoidosis: A curious association. Dis Colon Rectum 1981; 24:308.
  19. Smiéjan, JM, Cosnes, J, Chollet-Martin, S, et al. Sarcoid-like lymphocytosis of the lower respiratory tract in patients with active Crohn's disease. Ann Intern Med 1986; 104:17.
  20. Bewig, B, Manske, I, Bottcher, H, et al. Crohn's disease mimicking sarcoidosis in bronchoalveolar lavage. Respiration 1999; 66:467.
  21. Tanigawa, K, Sugiyama, K, Matsuyama, H, et al. Mesalazine-induced eosinophilic pneumonia. Respiration 1999; 66:69.
  22. Saltzman, K, Rossoff, LJ, Gouda, H, Tongia, S. Mesalamine-induced unilateral eosinophilic pneumonia. AJR Am J Roentgenol 2001; 177:257.
  23. Kasuga, I, Yanagisawa, N, Takeo, C, et al. Multiple pulmonary nodules in association with pyoderma gangrenosum. Respir Med 1997; 91:493.
  24. Rosenbaum, AJ, Murphy, PJ, Engel, JJ. Pleurisy during the course of ulcerative colitis. J Clin Gastroenterol 1983; 5:517.
  25. Solem, CA, Loftus, EV, Tremaine, WJ, Sandborn, WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004; 99:97.
  26. Bonderman, D, Jakowitsch, J, Adlbrecht, C, et al. Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. Thromb Haemost 2005; 93:512.
  27. Quera, R, Shanahan, F. Thromboembolism--an important manifestation of inflammatory bowel disease. Am J Gastroenterol 2004; 99:1971.
  28. Sonoda, K, Ikeda, S, Mizuta, Y, et al. Evaluation of venous thromboembolism and coagulation-fibrinolysis markers in Japanese patients with inflammatory bowel disease. J Gastroenterol 2004; 39:948.
  29. Miehsler, W, Reinisch, W, Valic, E, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?. Gut 2004; 53:542.
  30. Bonderman, D, Skoro-Sajer, N, Jakowitsch, J, et al. Predictors of outcome in chronic thromboembolic pulmonary hypertension. Circulation 2007; 115:2153.
  31. Bitton, A, Peppercorn, MA, Hanrahan, JP, Upton, MP. Mesalamine-induced lung toxicity. Am J Gastroenterol 1996; 91:1039.
  32. Foucher, P, Camus, P. Pneumotox online: the drug-induced lung diseases. (Available online at: www.pneumotox.com) Accessed: April 7, 2009.
  33. Hamadeh, M, Atkinson, J, Smith, LJ. Sulfasalazine-induced pulmonary disease. Chest 1992; 101:1033.
  34. Salerno, SM, Ormseth, EJ, Roth, BJ, et al. Sulfasalazine pulmonary toicity in ulcerative colitis mimicking clinical features of Wegener's granulomatosis. Chest 1996; 110:556.
  35. Ananthakrishnan, AN, Attila, T, Otterson, MF, et al. Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease. J Clin Gastroenterol 2007; 41:682.
  36. Keane, J, Gershon, S, Wise, RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor _-neutralizing agent. N Engl J Med 2001; 345:1098.
  37. Weatherhead, M, Masson, S, Bourke, SJ, et al. Interstitial pneumonitis after infliximab therapy for Crohn's disease. Inflamm Bowel Dis 2006; 12:427.
white circle LOG IN
white circle DEMO